Biogen Inc (BIIB)

Industry Drug Manufacturers - General


This stock can be held in an Investment ISA and an Investment Account
Sell

$247.00

Buy

$253.00

arrow-up$2.46 (+1.00%)

Prices updated at 21 Nov 2026, 00:55 EST
| Prices minimum 15 mins delay
|
Prices in USD

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also gen ...

Income statement

20242025
9,676m9,891m
7,366m7,486m
2,280m2,469m
23.5724.96
1,632m1,293m
2,830m2,604m
Sales, General and administrative2,404m2,434m
Interest expenses250m268m
Provision for income taxes274m264m
Operating expenses5,085m5,017m
Income before taxes1,906m1,557m
Net income available to common shareholders1,632m1,293m
11.218.83
Net interest income-183m-142m
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)11.188.79
Free cash flow per share12.114415.441
Book value/share112.2631124.0293
Debt equity ratio0.2920380.36026

Balance sheet

20242025
Current assets7,457m8,974m
Current liabilities5,529m3,349m
Total capital21,263m24,544m
Total debt6,630m6,577m
Total equity16,716m18,257m
Total non current liabilities--
Loans4,547m6,287m
Total assets28,049m29,440m
Total liabilities--
Cash and cash equivalents2,375m3,009m
Common stock146m147m

Cash flow

20242025
Cash at beginning of period1,050m2,375m
Cash dividends paid--
2,516m1,969m
Investments (gains) losses-799m-1,371m
2,375m3,009m
Net income--
2,876m2,205m
-360m-235m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.